1. Home
  2. HRMY vs DK Comparison

HRMY vs DK Comparison

Compare HRMY & DK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$35.24

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Delek US Holdings Inc.

DK

Delek US Holdings Inc.

HOLD

Current Price

$38.89

Market Cap

2.3B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
DK
Founded
2017
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Integrated oil Companies
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.3B
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
HRMY
DK
Price
$35.24
$38.89
Analyst Decision
Strong Buy
Hold
Analyst Count
9
15
Target Price
$50.56
$35.60
AVG Volume (30 Days)
934.4K
1.6M
Earning Date
11-04-2025
11-07-2025
Dividend Yield
N/A
2.62%
EPS Growth
50.44
N/A
EPS
3.17
N/A
Revenue
$825,944,000.00
$10,667,200,000.00
Revenue This Year
$20.68
N/A
Revenue Next Year
$15.93
N/A
P/E Ratio
$11.14
N/A
Revenue Growth
21.13
N/A
52 Week Low
$25.52
$11.03
52 Week High
$40.93
$43.50

Technical Indicators

Market Signals
Indicator
HRMY
DK
Relative Strength Index (RSI) 71.09 53.73
Support Level $32.77 $36.69
Resistance Level $36.20 $41.13
Average True Range (ATR) 1.11 2.13
MACD 0.17 -0.46
Stochastic Oscillator 81.04 37.90

Price Performance

Historical Comparison
HRMY
DK

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About DK Delek US Holdings Inc.

Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. It has two segments: Refining segment and Logistics segment. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.

Share on Social Networks: